timothy sykes logo
Moderna Stock Explodes As Phase 3 Cancer Vaccine Data Hits Thumbnail
G Google News

Moderna Stock Explodes As Phase 3 Cancer Vaccine Data Hits

BRYCE TUOHEY•UPDATED AUG. 21, 2026, 4:47 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Moderna Inc. stocks have been trading up by 9.13 percent amid strong optimism over its latest mRNA vaccine developments.

Key Takeaways

  • Shares of MRNA ripped as much as 177% in one day after late-stage skin cancer trial data turned the stock into the biggest gainer on the S&P 500.
  • Moderna and Merck reported their personalized mRNA cancer vaccine intismeran autogene plus Keytruda met primary and key secondary endpoints in the Phase 3 INTerpath-001 melanoma trial.
  • Bank of America hiked its MRNA price target from $40 to $170, calling the melanoma readout a watershed moment that broadens Moderna beyond infectious disease and eases capital concerns.
  • William Blair upgraded MRNA to Outperform as the melanoma program is expected to diversify revenue away from COVID-focused products while the stock spiked 70–80% premarket.
  • Across multiple reports, Moderna’s intismeran autogene combined with Keytruda delivered statistically significant, clinically meaningful survival benefits versus Keytruda alone in resected stage IIB–IV melanoma, with no new safety issues.

Candlestick Chart

Live Update At 16:47:12 EDT: On Friday, August 21, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 9.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRNA just went from quiet biotech to full-on momentum rocket. The daily chart shows Moderna trading under $60 for weeks, then detonating on 2026/08/19 with a run from an open near $116 to a close above $174. The follow-through has been wild — MRNA is now chopping in the $130–$160 zone, with recent closes around $145.13 after a high of $159.47, basically a new price universe for the ticker.

Under the hood, the financials still look like a classic high-risk, high-upside biotech story. Quarterly revenue sits at about $145M, with total revenue over the last period around $1.94B, but profitability is deep in the red. MRNA posted a quarterly net loss of roughly $782M and an EBITDA of about -$734M. Margins are ugly, with an EBIT margin around -139% and a profit margin near -140%.

More Breaking News

Yet the balance sheet matters for traders. Moderna carries low leverage, with total debt-to-equity at just 0.18 and a current ratio of 2.3. Cash and short-term investments total about $5.14B, giving MRNA time to execute its oncology plans. For active traders, this is a name where story and sentiment are driving price far more than current earnings.

Why Traders Are Watching MRNA After The Melanoma Shockwave

This entire MRNA move is about one thing: confirmation that its mRNA tech works in cancer, not just in COVID. Moderna and Merck announced that their individualized cancer vaccine, intismeran autogene (also known as V940/mRNA-4157), combined with Keytruda, hit both its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in completely resected stage IIB–IV melanoma.

That language sounds clinical, but for traders it means this: patients on the MRNA–Merck combo are staying cancer-free longer and seeing fewer distant metastases than those on Keytruda alone. Multiple reports stress the effect was “statistically significant and clinically meaningful,” and just as important, no new safety issues popped up. This is the first positive Phase 3 readout for an mRNA-based cancer therapy. That is why MRNA re-rated overnight.

The market reaction has been violent. Several intraday reads show Moderna shares up between 113% and 177%, with MRNA tagging the biggest-gainer spot on the S&P 500. Intraday five-minute candles on 2026/08/21 show huge liquidity and wide ranges, with spikes toward $159 and heavy volume through the mid-day session before settling around the mid-$140s. That kind of action screams momentum trading, not slow repositioning.

Wall Street is chasing the story. Bank of America moved MRNA from Underperform to Neutral and slammed its price target from $40 up to $170, explicitly calling the melanoma data a “watershed moment” that shifts Moderna beyond infectious disease and eases capital worries. William Blair flipped to Outperform, highlighting how this cancer program finally diversifies MRNA’s revenue narrative away from fading COVID demand.

For active traders, the takeaway is simple: MRNA has transitioned from “broken COVID chart” to a high-beta oncology platform play. The news flow, upgrades, and chart all line up to keep this ticker on every momentum watchlist.

Conclusion

MRNA now sits at the intersection of hype and hard data. The INTerpath-001 Phase 3 melanoma win gives Moderna and Merck a real shot at regulatory filings across multiple tumor types, not just a science experiment. With intismeran autogene plus Keytruda delivering better recurrence-free and distant metastasis-free survival versus Keytruda alone, MRNA has locked in validation that traders have been waiting on for years.

At the same time, the numbers remind everyone this is still a burner. Moderna is losing hundreds of millions of dollars per quarter, sporting negative operating margins, and leaning on a rich price-to-sales ratio above 30. But that $5B-plus cash pile and modest leverage give MRNA room to build an oncology franchise if the regulators and future trials cooperate.

For traders, the strategy now is about discipline. MRNA has already moved from the $50s into the $140s–$170s zone in days. That is textbook extended. Chasing without a plan can wreck an account, even on “great” news. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” Tim Sykes hammers this home all the time: “Big news plus big volume can create amazing opportunities, but the only traders who last are the ones who cut losses quickly and never fall in love with a story.”

This move in MRNA is a case study. The story is huge, the volatility is real, and the edge goes to traders who respect both. This content is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”